Achaogen Inc.

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development and commercialization of innovative antibacterial treatments against multi-drug resistant (MDR), gram-negative infections. The company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI), bloodstream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).